Literature DB >> 17294611

Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

B A Parmenter1, B Weinstock-Guttman, N Garg, F Munschauer, R H B Benedict.   

Abstract

Cognitive impairment is common in multiple sclerosis (MS), yet difficult to detect during routine neurologic examination. Therefore, brief screening tests that identify patients who may benefit from a more thorough assessment or treatment are needed. We investigated the utility of the Symbol Digit Modalities Test (SDMT) as a screen for cognitive dysfunction because it can be administered and scored in about 5 minutes. One hundred MS patients and 50 healthy controls, matched on demographic variables, participated in the study. Examination procedures included the neuropsychological (NP) tests included in the Minimal Assessment of Cognitive Function in MS (MACFIMS) battery. Patients were considered impaired if they performed one and a half standard deviations below controls on two or more MACFIMS variables, excluding the SDMT. Bayesian statistics showed that a total score of 55 or lower on the SDMT accurately categorized 72% of patients, yielding sensitivity of 0.82, specificity of 0.60, positive predictive value (PPV) of 0.71, and negative predictive value (NPV) of 0.73. These results suggest that the effectiveness of the SDMT as a screen for cognitive impairment in MS is roughly equal to that of other psychometric and questionnaire methods.

Entities:  

Mesh:

Year:  2007        PMID: 17294611     DOI: 10.1177/1352458506070750

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  79 in total

1.  Validity of a computerized version of the symbol digit modalities test in multiple sclerosis.

Authors:  Nadine Akbar; Kimia Honarmand; Nancy Kou; Anthony Feinstein
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

2.  Validity of brief screening tools for cognitive impairment in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Laura J Julian; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Edward Yelin; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

3.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

Review 4.  Reliability and validity of neuropsychological screening and assessment strategies in MS.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

Review 5.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

6.  Regression-Based Norms for the Symbol Digit Modalities Test in the Dutch Population: Improving Detection of Cognitive Impairment in Multiple Sclerosis?

Authors:  Jessica Burggraaff; Dirk L Knol; Bernard M J Uitdehaag
Journal:  Eur Neurol       Date:  2017-03-21       Impact factor: 1.710

7.  Analysis of "task-positive" and "task-negative" functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis.

Authors:  C Forn; M A Rocca; I Boscá; B Casanova; A Sanjuan; M Filippi
Journal:  Exp Brain Res       Date:  2013-01-04       Impact factor: 1.972

8.  Visual search as a tool for a quick and reliable assessment of cognitive functions in patients with multiple sclerosis.

Authors:  Kathrin S Utz; Thomas M A Hankeln; Lena Jung; Alexandra Lämmer; Anne Waschbisch; De-Hyung Lee; Ralf A Linker; Thomas Schenk
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

9.  Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Authors:  Lin Chen; Jun Hua; Christopher A Ross; Shuhui Cai; Peter C M van Zijl; Xu Li
Journal:  J Neurosci Res       Date:  2018-11-29       Impact factor: 4.164

10.  Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Authors:  Sarah A Morrow; Heather Rosehart
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.